Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of VEAB Ventilation Entreprenad
Mandate

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of VEAB Ventilation Entreprenad

June 28, 2021 Employment and Benefits M&A Real Estate and Construction Banking and Finance

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Ventilation Entreprenad VEAB, Veab Ventilation Entreprenad i Kristianstad, VEAB Ventilation Entreprenad I Helsingborg, Styr Entreprenad i Malmö and Energi & Klimatteknik i Tygelsjö.

The companies provide contracting services related to ventilation as well as service on real estate technical installations, and are based in Skåne. Together, the companies have a turnover of approximately SEK 370 million. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted of partner Christina Kokko together with Karl Klackenberg, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Construction), Elin Broman (Employment), Karl-Gustaw Tobola (Financing) and Frida Ställborn (Real Estate).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026